Laboratorio de Inmunología, Departamento de Fisiología, Centro Universitario de, Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.
Cancer Cell Int. 2013 Oct 22;13(1):103. doi: 10.1186/1475-2867-13-103.
The altered expression of prolactin (PRL) and its receptor (PRLR) has been implicated in breast and other types of cancer. There are few studies that have focused on the analysis of PRL/PRLR in cervical cancer where the development of neoplastic lesions is influenced by the variation of the hormonal status. The aim of this study was to evaluate the expression of PRL/PRLR and the effect of PRL treatment on cell proliferation and apoptosis in cervical cancer cell lines.
High expression of multiple PRLR forms and PRLvariants of 60-80 kDa were observed in cervical cancer cell lines compared with non-tumorigenic keratinocytes evaluated by Western blot, immunofluorecence and real time PCR. Treatment with PRL (200 ng/ml) increased cell proliferation in HeLa cells determined by the MTT assay at day 3 and after 1 day a protective effect against etoposide induced apoptosis in HeLa, SiHa and C-33A cervical cancer cell lines analyzed by the TUNEL assay.
Our data suggests that PRL/PRLR signaling could act as an important survival factor for cervical cancer. The use of an effective PRL antagonist may provide a better therapeutic intervention in cervical cancer.
催乳素（PRL）及其受体（PRLR）的表达改变与乳腺癌和其他类型的癌症有关。很少有研究集中在分析宫颈癌中的 PRL/PRLR，其中肿瘤病变的发展受激素状态变化的影响。本研究旨在评估 PRL/PRLR 的表达以及 PRL 处理对宫颈癌细胞系细胞增殖和凋亡的影响。
通过 Western blot、免疫荧光和实时 PCR 分析，与非肿瘤性角质形成细胞相比，在宫颈癌细胞系中观察到多种 PRLR 形式和 60-80 kDa 的 PRL 变体高表达。用 PRL（200ng/ml）处理可通过 MTT 测定在第 3 天增加 HeLa 细胞的增殖，在用 TUNEL 测定分析时，在用依托泊苷诱导凋亡后 1 天，对 HeLa、SiHa 和 C-33A 宫颈癌细胞系具有保护作用。
我们的数据表明，PRL/PRLR 信号可能是宫颈癌的一个重要生存因素。使用有效的 PRL 拮抗剂可能为宫颈癌提供更好的治疗干预。
